Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
IPO Year:
Exchange: NASDAQ
Website: nektar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/24/2026 | $70.00 | Neutral | Wedbush |
| 3/17/2026 | Buy | TD Cowen | |
| 2/10/2026 | Mkt Perform → Outperform | William Blair | |
| 11/26/2025 | $102.00 | Buy | Citigroup |
| 6/24/2025 | $60.00 → $100.00 | Buy | BTIG Research |
| 6/24/2025 | $6.50 → $120.00 | Buy | H.C. Wainwright |
| 4/11/2025 | $2.00 | Hold → Buy | Jefferies |
| 3/14/2025 | $6.00 | Perform → Outperform | Oppenheimer |
| 1/8/2025 | $4.00 | Buy | B. Riley Securities |
| 12/10/2024 | $6.50 | Buy | H.C. Wainwright |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
SCHEDULE 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
SCHEDULE 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
DEFA14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
DEF 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
424B5 - NEKTAR THERAPEUTICS (0000906709) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wedbush initiated coverage of Nektar Therapeutics with a rating of Neutral and set a new price target of $70.00
TD Cowen initiated coverage of Nektar Therapeutics with a rating of Buy
William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform
Citigroup initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $102.00
BTIG Research reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $100.00 from $60.00 previously
H.C. Wainwright reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $120.00 from $6.50 previously
Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00
Oppenheimer upgraded Nektar Therapeutics from Perform to Outperform and set a new price target of $6.00
B. Riley Securities initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
H.C. Wainwright initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $6.50
Fastest customizable press release news feed in the world
SAN FRANCISCO, June 3, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on May 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 11,900 shares of its common stock to five newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Nektar
SAN FRANCISCO, May 27, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that company management will be webcasting its participation in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York. 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 – webcast to be available at 1:20 p.m. Eastern Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A
SAN FRANCISCO, May 7, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2026. Cash and investments in marketable securities on March 31, 2026, were $731.6 million as compared to $245.8 million on December 31, 2025. Nektar's cash and marketable securities at March 31, 2026, exclude net proceeds of approximately $351 million from the secondary offering completed by the Company on April 23, 2026."2026 is shaping up to be a defining year for Nektar and for our lead biologic candidate rezpegaldesleukin," said
SAN FRANCISCO, May 1, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on April 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 28,450 shares of its common stock and 2,950 restricted stock units (RSUs) to six newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an emp
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The we
SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced the closing of its underwritten public offering of $373.8 million of shares of its common stock. Nektar sold 4,062,500 shares of common stock in the offering, which includes 529,891 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The shares of common stock were sold at a public offering price of $92.00 per share. The gross proceeds to Nektar from the offering were approximately $373.8 million, before deducting underwritin
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten public offering of $325 million of shares of its common stock. Nektar is selling 3,532,609 shares of common stock at a public offering price of $92.00 per share. The gross proceeds to Nektar from the offering are expected to be approximately $325 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Nektar has granted the underwriters a 30-day option to purchase up to an additional
SAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten public offering of $250,000,000 of its shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Nektar. In addition, Nektar intends to grant the underwriters a 30-day option to purchase up to an additional $37,500,000 of shares of its common stock at the p
29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatmentIncreasing proportions of patients achieved clinically meaningful hair growth thresholds across numerous SALT measurements with 94% of patients completing treatment extensionFavorable safety profile with twice-monthly dosing maintained throughout 52 weeks, consistent with previously reported resultsResults support advancement of rezpegaldesleukin into late-stage development in alopecia areataSAN FRANCISCO, April 20, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on d
SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Monday, April 20, 2026 at 8:00 am ET / 5:00 am PT. Conference Call The results will be provided
Live Leadership Updates
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple
SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO). In his role as CMO, Dr. Nuyten will have oversight for the company's clinical strategy and activities, including direct supervision of clinical sciences, clinical operations, data science and systems, medical affairs and clinical pharmacology. Dr. Nuyten will also serve as a member of the Company's Executive Committee. Dr. Nuyten has extensive experience establishing an
SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately. Since 2017, Dr. Kotzin has served as Senior Vice President, Clinical Development and Head of Immunology at Nektar. Wei Lin will be leaving the company to pursue another opportunity. (PRNewsfoto/Nektar Therapeutics) "We are pleased that Dr. Kotzin will take on this key role on our development team at Nektar," said Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics. "Since he joined Nektar in 2017, Dr. Kotzin has demonstrated strong leadership and strate
This live feed shows all institutional transactions in real time.
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
Live finance-specific insights
SAN FRANCISCO, April 28, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 7, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The we
SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Monday, April 20, 2026 at 8:00 am ET / 5:00 am PT. Conference Call The results will be provided
SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web
71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses observed across key efficacy endpoints at week 52 with both monthly and quarterly dosing, including an up to 5-fold increase in EASI-100 response rates Favorable safety profile consistent with previously reported results for rezpegaldesleukin Durability of maintained response rates supports advancement to pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing Data validate novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator Confere
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT. Conference Call The results will be provided in a mo
Achieved target product profile on the primary endpoint, with a mean percent reduction in SALT score at 36 weeks of 28.2% in the 24 µg/kg arm versus 11.2% in placebo Mean percent reduction in SALT scores at 36 weeks was 30% for both treatment arms versus 6% for placebo, achieving statistical significance (p<0.05) when excluding four patients that did not meet major study eligibility criteria at baseline Safety profile showed rezpegaldesleukin was well tolerated and was consistent with previously reported results Study results establish Phase 3 dose and support planned advancement to Phase 3 development in alopecia areata Conference call and webcast with management and alopecia areata exper
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Tuesday, December 16, 2025 at 8:00 am ET / 5:00 am PT. Conference Call The results will be provided i
SAN FRANCISCO, Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/.
SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. T
Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for key secondary endpoints at week 16 of disease reduction, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA Rapid onset of EASI reduction and magnitude of itch improvement show potential differentiation of this novel regulatory T-cell mechanism as a first and best-in-class immune-modulator Robust dose-dependent reduction of inflammatory biomarkers in atopic dermatitis including TARC/CCL17, periostin, MDC/CCL22, and IL-19 Safety profile consistent with previously reported results Data expec